Thus, roscovitine in combination with either rapamycin or sorafenib can prevent the development of the aberrant acinar phenotypes caused by LMW-E expression, confirming a role for LMW-E/CDK2 kinase activity in causing formation of large, multilobular acini and demonstrating a potential therapeutic approach to treat cancer patients with high LMW-E expression. Here, CDK2 is linked to cancer.